Novel On-body Evaluation of Cardiac Health for Oncology
NCT ID: NCT07158450
Last Updated: 2026-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
50 participants
OBSERVATIONAL
2025-10-09
2026-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors
NCT02615054
Automated Left Ventricular Function Evaluation by LVivoEF
NCT01515267
Exploratory Study of the Diagnostic Potential of an Innovative Thoracic Vibration Analysis Technique
NCT06661200
AI-based Prediction of Cardiac Function Using Echocardiography and Body Composition Data (ECHO-FIT Study)
NCT06811519
DIGIPREDICT-Physio-DE
NCT05886569
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy
No known or suspected cardiac disease
No interventions assigned to this group
Borderline LVEF
Known conditions that may predispose to LV dysfunction, but no prior diagnosis of reduced left ventricular ejection fraction
No interventions assigned to this group
Reduced LVEF
Known diagnosis of reduced left ventricular ejection fraction
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willing and able to provide informed consent prior to any study-related activity
Exclusion Criteria
* Have been diagnosed with one or more of the following cardiac diseases/conditions that distort cardiac activity:
1. Severe valve disease
2. Severe right ventricular dilation or dysfunction
3. Significant arrhythmias or conduction abnormalities
4. Active ischemia or myocardial infarction within the last 3 months
* Have an active implantable cardiac device
* Have any condition that would cause inaccurate TTE measurements
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Rochester
OTHER
Skribe Medical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Strong Memorial Hospital
Rochester, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SKR-LVEF-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.